Skip to main content

Table 1 Baseline characteristics of studies included in the meta-analysis

From: Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis

Author and year of publication

Study design

sample size

Age (mean ± SD)

Sex

Duration (days)

Dosage (mg)

 

Jadad scores

LV

V

L

LV/V/L

male/female

L

V

Interventions

Outcomes

Chen M, 201 8[18]

RCT

32

33

31

71.41 ± 7.52/ 70.92 ± 7.24/ 71.93 ± 7.05

48/48

14

600

80

LV/V/L

3

Deng GJ,201 8[19]

RCT

40

40

40

47.3 ± 4.15/ 46.2 ± 5.89/ 47.8 ± 4.03

55/65

14

300

80

LV/V/L

3

Huo Y, 201 4[20]

RCT

60

60

44.4 ± 4.2

57/63

14

600

80

LV/V

4

Jiang ZY,201 9[21]

RCT

51

51

69.21 ± 3.54

59/43

14

600

80

LV/V

4

Li Y, 201 8[22]

RCT

43

43

63.21 ± 3.43/62.47 ± 3.65

52/34

14

600

80

LV/V

4

Lin XJ,201 3[23]

RCT

33

40

35

61/47

14

600

80

LV/V/L

2

Ma L, 201 9[24]

RCT

48

48

57.26 ± 4.31/ 57.84 ± 3.92

56/40

14

600

80

LV/V

4

Peng B, 201 3[25]

RCT

40

40

40

14

450

80

LV/V/L

3

Shi D, 201 8[26]

RCT

135

135

61.71 ± 2.52/ 61.56 ± 2.51

131/139

14

600

80

LV/V

3

Wen WB,201 9[27]

RCT

26

25

56 ± 11/56 ± 9

17/14

14

300

80

LV/V

3

Zhao J, 201 7[28]

RCT

41

39

46.53 ± 13.35/45.78 ± 12.28

50/30

14

600

80

LV/V

4

  1. Note: RCT, randomized controlled trial; L, lipoic acid; V, Valsartan; LV, lipoic acid+ Valsartan; UAER = Urinary albumin excretion rate, Urinary albumin, β2-MG = β2-microglobulin, hs-CRP = Hypersensitive C-reactive protein, SOD = Superoxide dismutase, MDA = malondialdehyde, T-AOC = total antioxidant capacity